ArticleInfection and drug resistance2025
Clinical and Demographic Characteristics of Hospitalized Pediatric Measles Cases; The 2023 Outbreak in Northern Jordan.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hospital burden and clinical features associated with admission among confirmed measles cases during the 2025-2026 outbreak at a tertiary care hospital in Mexico.IJID regions · 2026Article
- Machine Learning-Based Severity Stratification for Smart Preventive Decision Support: Evidence from Measles Surveillance in a Resource-Constrained Region.Journal of clinical medicine · 2026Article
- Resurgent measles in Türkiye: predictors of severe disease in a nationwide paediatric cohort, 2023.European journal of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Measles remains a leading vaccine-preventable cause of childhood morbidity and mortality globally. Despite immunization efforts, outbreaks persist, including a 2023 outbreak in Irbid, Jordan. Objective: To describe the clinical, demographic, and vaccination characteristics of pediatric measles patients hospitalized during the 2023 Irbid outbreak and assess complications and outcomes. Methods: A retrospective observational study included all children (0-14 years) hospitalized with laboratory-confirmed measles at Princess Rahma Pediatric Hospital, Irbid, from April to December 2023. Data on demographics, vaccination status, symptoms, complications, management, and outcomes were analyzed using descriptive statistics and comparisons between vaccinated/unvaccinated groups. Results: Of 63 hospitalized children, 61.9% were under one year old, and 49.2% were male. Most (63.5%) were unvaccinated; 47.6% of these were ineligible due to age (<9 months). Among eligible children (≥9 months), 27.2% were fully vaccinated, 42.5% under-vaccinated, and 30.3% unvaccinated. Fever (95.2%) and rash (96.8%) were the most common symptoms. Pulmonary complications affected 68.3% (bronchopneumonia: 55.5%; pneumonia: 12.7%). Dehydration (34.9%) and gastrointestinal symptoms (vomiting: 30.1%; diarrhea: 28.5%) were frequent. One unvaccinated 7-month-old infant died from measles-associated pneumonia. Vitamin A was administered to all patients, and 82.5% received empirical antibiotics. The average hospital stay was 4.4 days. Conclusion: The measles outbreak in Northern Jordan predominantly affected unvaccinated children, particularly those under nine months of age. While vaccination reduced the risk of severe complications (eg, pneumonia occurred in 75% of unvaccinated vs 25% of vaccinated cases), breakthrough infections in vaccinated children underscore the need for optimized immunization strategies. Respiratory complications, including pneumonia, were the leading cause of hospitalization and mortality, highlighting the vaccine's critical role in mitigating disease severity. Strengthening vaccination coverage and revisiting age-specific policies in high-risk regions remain essential to reduce measles-related morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.